Last reviewed · How we verify
Standard Sunscreen
Standard Sunscreen, marketed by Yale University, holds a position in the sunscreen market with a key composition patent expiring in 2028. The product's key strength lies in its established market presence and patent protection. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Standard Sunscreen |
|---|---|
| Sponsor | Yale University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Emulsion 8-Week Anti-acne Efficacy Clinical Study (NA)
- Efficacy and Tolerability of a Hybrid Fractional Laser for the Treatment of Acne Scars in Patients With Skin of Color (NA)
- Natural Sunlight Protection and Simulated Sunlight Protection Offered by Sunscreens and Fabrics (NA)
- 12-Week Efficacy Clinical Study of Serum (NA)
- The Relationship Between Microbioma Balance and Acne Vulgaris as a New Acne Treatment (PHASE2)
- A Clinical Study to Assess the Safety, In-use Tolerability of Test Product in Healthy Adult Subjects With Dry and Sensitive Skin. (NA)
- Impact of Sunscreen Dispensers in Parks Visited by Teenagers (NA)
- Clinical Study to Evaluate the 80-Minute Water Resistant Sun Protection Factor (SPF) of Sunscreen Products (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard Sunscreen CI brief — competitive landscape report
- Standard Sunscreen updates RSS · CI watch RSS
- Yale University portfolio CI